Liquid biopsies are no longer confined to oncology—their versatility is being harnessed to detect and monitor other diseases, from infectious illnesses to autoimmune conditions. This expansion reflects a broader shift in diagnostics, where non-invasive methods are being explored for their potential to improve access and patient outcomes.

Recent research focuses on liquid biopsies for transplant rejection. A 2024 study in Science Translational Medicine used plasma cfDNA methylation patterns to detect kidney transplant rejection with 85% accuracy, reducing reliance on invasive tissue biopsies. For infectious diseases, tests are being developed to identify viral or bacterial DNA in blood, enabling faster diagnosis of conditions like hepatitis B or sepsis. Early trials show these tests can detect pathogens 2–3 days earlier than traditional PCR methods.

The "liquid biopsy applications beyond oncology" are also gaining traction in reproductive health. For example, non-invasive prenatal testing (NIPT) uses cfDNA from maternal blood to screen for fetal genetic disorders, a liquid biopsy application already widely adopted. MarketResearchFuture estimates that non-oncology uses will account for 25% of the liquid biopsy market by 2030, driven by research into neurodegenerative diseases (e.g., Alzheimer’s) and metabolic disorders. To explore how liquid biopsies are transforming other medical fields, refer to the report: liquid biopsy applications beyond oncology

This expansion underscores liquid biopsies’ adaptability. As research uncovers new biomarkers, these tests will become essential across more specialties, fostering a diagnostic ecosystem where a single blood draw can provide insights into multiple health conditions. For patients, this means less invasive care and more holistic health monitoring—a future that is rapidly becoming a reality.